Shares of Pulmonx Corp are experiencing significant upward momentum following a notably optimistic research note from D. Boral Capital. The firm established a $16.00 price target on the medical technology company, suggesting substantial appreciation potential from current trading levels.
Revised Annual Guidance Presents Cautious Outlook
The company reported its second-quarter 2025 financial results on July 30. While global revenue increased by 15% year-over-year to $23.9 million, management subsequently revised its full-year guidance downward.
The updated projections include:
– 2025 Revenue: $90-92 million (previously $96-98 million)
– 2025 Gross Margin: Approximately 74%
– 2025 Operating Expenses: $128-130 million (reduced from $133-135 million)
– Cash Position (June 30, 2025): $84.2 million
This more conservative forecast reflects tempered expectations for U.S. sales performance while maintaining stable margin projections.
Should investors sell immediately? Or is it worth buying Pulmonx Corp?
Analyst Consensus Indicates Strong Confidence
Market researchers remain overwhelmingly positive about Pulmonx’s long-term prospects. The consensus rating stands at “Moderate Buy,” with several firms reaffirming their “Buy” recommendations. The average price target among analysts reaches $9.60, implying potential gains exceeding 400%. The most optimistic assessment comes in at $18.00 per share.
D. Boral Capital’s September 8 evaluation particularly stands out, indicating significant potential valuation expansion for the innovative medical device manufacturer.
Management Maintains Investor Engagement Strategy
Pulmonx continues to prioritize transparency through regular investor communications. The company recently participated in the Wells Fargo Healthcare Conference on September 4 and has scheduled one-on-one meetings for the Lake Street Best Ideas Growth Conference on September 11.
These engagements demonstrate management’s commitment to maintaining open dialogue with the investment community, particularly important for a company revolutionizing lung disease treatment through groundbreaking technologies including the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System.
Ad
Pulmonx Corp Stock: Buy or Sell?! New Pulmonx Corp Analysis from February 7 delivers the answer:
The latest Pulmonx Corp figures speak for themselves: Urgent action needed for Pulmonx Corp investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Pulmonx Corp: Buy or sell? Read more here...
